Citations

Showing 10 of 108094 citations.

Chronic graft‐versus‐host disease: Current management paradigm and future perspectives
Mawardi, Hani , Hashmi, Shahrukh K. , Elad, Sharon, Aljurf, Mahmoud , Treister, Nathaniel S. , Elad, Sharon

Mayo Clinic

Oral Diseases | July 9, 2018 | Volume: 25 | Issue: 4 | Pages: 931-948

10.1111/odi.12936 | PMID 29984442 Get It

AbstractIntroductionThe field of allogeneic hematopoietic cell transplantation (allo‐HCT) began in the 1950s, and despite a seven decade history of remarkable clinical advances, graft‐versus‐host‐disease (GVHD) remains the greatest obstacle in its success due to considerable morbidity and mortality. Graft‐versus‐host disease is the second leading cause of transplantation‐related mortality (TRM) after relapse of primary disease. There are two main types of GVHD—acute and chronic—differing in the pathogenesis, time of onset, and clinical presentation.ObjectiveThis review provides a comprehensive overview of chronic GVHD pathophysiology and current management paradigms, as well as consideration of promising novel therapies.ConclusionChronic GVHD is a serious disease which may be active for years, or even decades, requiring potentially years of immunosuppressive therapies and placing patients at risk for a number of late complications. While the oral cavity has long been recognized to be a prominent target of GVHD, and in particular, chronic GVHD, it must be recognized and appreciated that it is a complex systemic disease with a wide spectrum of clinical manifestations.
Harmonization of technology across an integrated delivery network
Anderson, Jared , Cooley, T., Torre, Charlie De la, Rocco, James Anthony Della, Dorn, Mitchell, Ferer, Darren S., Friudenberg, Patrick, Ganio, Michael C, Lim, Dennison, McGregory, Michael E., Nickman, Nancy A. , Schenkat, Daniel H, Shah, Shailly, Tjhio, David, Urbanski, Chris, Volpe, Gwen

Mayo Clinic

American Journal of Health-System Pharmacy | July 9, 2018 | Volume: 75 | Issue: 14 | Pages: 1073-1078

10.2146/ajhp170301 | PMID 29987061 Get It

Periprocedural Cardiopulmonary Bypass or Venoarterial Extracorporeal Membrane Oxygenation During Transcatheter Aortic Valve Replacement: A Systematic Review
Vallabhajosyula, Saraschandra , Patlolla, Sri Harsha , Vallabhajosyula, Saarwaani , Barsness, Gregory W. , Greason, Kevin L. , Holmes, David R. , Eleid, Mackram F. , Sandhyavenu, Harigopal , Dunlay, Shannon M. , Vallabhajosyula, Saraschandra , Harsha Patlolla, Sri

Mayo Clinic

Journal of the American Heart Association | July 9, 2018 | Volume: 7 | Issue: 14 | Pages: No page available

10.1161/jaha.118.009608 | PMID 29987125 Get It

Background There are limited data on the use of venoarterial extracorporeal membrane oxygenation ( VA ‐ ECMO ) or cardiopulmonary bypass ( CPB ) to provide hemodynamic support periprocedurally during transcatheter aortic valve replacement. This study sought to evaluate patients receiving transcatheter aortic valve replacement with concomitant use of CPB / VA ‐ ECMO . Methods and Results We systematically reviewed the published literature from 2000 to 2018 for studies evaluating adult patients requiring CPB / VA ‐ ECMO periprocedurally during transcatheter aortic valve replacement. Studies reporting short‐term and long‐term mortality were included. Given the significant methodological and statistical differences between published studies, meta‐analysis of the association of CPB / VA ‐ ECMO with mortality was not performed. Of the 537 studies identified, 9 studies representing 5191 patients met our inclusion criteria. Median ages were between 75 and 87 years with 33% to 75% male patients. Where reported, the Edwards SAPIEN ™ transcatheter heart valve was the most frequently used. A total of 203 (3.9%) patients received periprocedural hemodynamic support with CPB / VA ‐ ECMO . Common indications for CPB / VA ‐ ECMO included left ventricular or aortic annular rupture, rapid hemodynamic deterioration, aortic regurgitation, cardiac arrest, and left main coronary artery obstruction. The use of CPB / VA ‐ ECMO was predominantly an emergent strategy and was used for durations of 1 to 2 hours. Short‐term mortality (in‐hospital and 30‐day) was 29.8%, and 1‐year mortality was 52.4%. Major complications such as bleeding, vascular injury, tamponade, stroke, and renal failure were noted in 10% to 50% of patients. Conclusions CPB / VA ‐ ECMO was used in 4% in the early experience of patients undergoing transcatheter aortic valve replacement, most commonly for periprocedural complications. There are limited data on preprocedural planned use of VA ‐ ECMO , and the characteristics of this population remain poorly defined.
Intrapulmonary Vein Ablation Without Stenosis: A Novel Balloon‐Based Direct Current Electroporation Approach
Witt, Chance M. , Sugrue, Alan , Padmanabhan, Deepak , Vaidya, Vaibhav R. , Gruba, Sarah M., Rohl, James, Killu, Ammar M. , Naksuk, Niyada , Pederson, Joanne, Suddendorf, Scott H., Ladewig, Dorothy J., Maor, Elad , Holmes, David R. , Asirvatham, Samuel J. , Vaidya, Vaibhav, Suddendorf, Scott, Kapa, Suraj , Asirvatham, Samuel J , Maor, Elad , DeSimone, Christopher V.

Mayo Clinic

Journal of the American Heart Association | July 9, 2018 | Volume: 7 | Issue: 14 | Pages: No page available

10.1161/jaha.118.009575 | PMID 29987121 Get It

Background Current thermal ablation methods for atrial fibrillation, including radiofrequency and cryoablation, have a suboptimal success rate. To avoid pulmonary vein (PV) stenosis, ablation is performed outside of the PV, despite the importance of triggers inside the vein. We previously reported on the acute effects of a novel direct current electroporation approach with a balloon catheter to create lesions inside the PVs in addition to the antrum. In this study, we aimed to determine whether the effects created by this nonthermal ablation method were associated with irreversible lesions and whether PV stenosis or other adverse effects occurred after a survival period. Methods and Results Initial and survival studies were performed in 5 canines. At the initial study, the balloon catheter was inflated to contact the antrum and interior of the PV. Direct current energy was delivered between 2 electrodes on the catheter in ECG‐gated 100 μs pulses. A total of 10 PVs were treated demonstrating significant acute local electrogram diminution (mean amplitude decrease of 61.2±19.8%). After the survival period (mean 27 days), computed tomography imaging showed no PV stenosis. On histologic evaluation, transmural, although not circumferential, lesions were seen in each treated vein. No PV stenosis or esophageal injury was present. Conclusions Irreversible, transmural lesions can be created inside the PV without evidence of stenosis after a 27‐day survival period using this balloon‐based direct current ablation approach. These early data show promise for an ablation approach that could directly treat PV triggers in addition to traditional PV antrum ablation.
DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition
Hubers, Scott , Wilson, Jessica R. , Nian, Hui , Grouzmann, Eric , Eugster, Philippe J. , Shibao, Cyndya A. , Billings, Frederic T. , Kerman, Scott Reza Jafarian , Hubers, Scott A, Kerman, Scott Jafarian , Eugster, Philippe J , Yu, Chang , Shibao, Cyndya A , Brown, Nancy J.

Mayo Clinic

Hypertension | July 9, 2018 | Volume: 72 | Issue: 3 | Pages: 712-719

10.1161/hypertensionaha.118.11498 | PMID 29987109 Get It

DPP (dipeptidyl peptidase)-4 inhibitors are antidiabetic drugs that may increase heart failure in high-risk patients. NPY (neuropeptide Y) is coreleased with norepinephrine, causes vasoconstriction via the Y1 receptor, and is degraded by DPP4 to NPY (3–36) in vitro. NPY (3–36) decreases release of norepinephrine via the Y2 receptor. We tested the hypothesis that DPP4 inhibition would potentiate the vasoconstrictor effect of NPY. Eighteen nonsmokers (12 healthy controls and 6 with type 2 diabetes mellitus) participated in 1 of 2 randomized, double-blind, placebo-controlled crossover studies. First, subjects were randomized to order of treatment with sitagliptin 100 mg/d versus placebo for 7 days separated by 4-week washout. On the last day of treatment, NPY was infused by brachial artery and forearm blood flow was measured using plethysmography. Blood samples were collected after each dose. NPY infusions were repeated after 90-minute washout and intra-arterial enalaprilat. Second, 5 healthy subjects were randomized to crossover treatment with sitagliptin 100 mg/d plus valsartan 160 mg/d versus placebo plus valsartan. NPY infusions were performed on the seventh day of treatment. NPY caused dose-dependent vasoconstriction. During enalaprilat, sitagliptin significantly potentiated NPY-induced vasoconstriction in controls and diabetics ( P ≤0.02 for forearm blood flow in either group). Baseline norepinephrine release was increased during sitagliptin and enalaprilat, but not further by NPY. Sitagliptin increased the ratio of NPY to NPY (3–36). During valsartan, sitagliptin also significantly potentiated NPY-induced vasoconstriction ( P =0.009 for forearm blood flow). Potentiation of endogenous NPY could contribute to cardiovascular effects of DPP4 inhibitors in patients taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
Diagnosis, assessment, and management of surgical complications following esophagectomy
Grimminger, Peter , Bergeat, Damien , Bertheuil, Nicolas , Chandramohan, Servarayan Murugesan, Chen, Ke‐Neng , Chon, Seung‐Hun , Collet, Denis, Goh, Khean‐Lee, Gronnier, Caroline , Liu, J F, Nafteux, P., Pirchi, Enrique D, Schiesser, Marc , Wu, Aaron , Wu, Peter , Buttar, Navtej , Chang, Andrew C. , Grimminger, Peter P , Chang, Andrew C , Goense, Lucas , Gockel, Ines , Meunier, Bernard , Thieme, René

Mayo Clinic

Annals of the New York Academy of Sciences | July 9, 2018 | Volume: 1434 | Issue: 1 | Pages: 254-273

10.1111/nyas.13920 | PMID 29984413 Get It

AbstractDespite improvements in operative strategies for esophageal resection, anastomotic leaks, fistula, postoperative pulmonary complications, and chylothorax can occur. Our review seeks to identify potential risk factors, modalities for early diagnosis, and novel interventions that may ameliorate the potential adverse effects of these surgical complications following esophagectomy.
Patient Discomfort and Resident Confidence After Knee Intra-articular Injection Simulation Training: A Randomized Control Trial Study
Amoako, Adae , Pujalte, George G.A. , Riley, Timothy D. , Pujalte, George GA, Pujalte, George , Kaushik, Neha

Mayo Clinic

Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders | July 9, 2018 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/1179544118782903 | PMID 30013410 Get It

Teaching primary care providers how to perform musculoskeletal procedures has become increasingly important as more and more patients with orthopedic conditions present in primary care clinics. This study aims to evaluate whether targeted simulation model training in residency can increase residents’ comfort level in performing intra-articular knee injections and decrease the pain of the procedure, as reported by patients injected. Residents were randomized into intervention and control groups. The comfort level of the residents as well as the pain levels from the procedures, as reported by patients, was recorded. The mean comfort level for the intervention group was 1.2, compared with that in the control group, which was 2.13; P value was .047. The mean pain level in the intervention group was 1.8, whereas in the control group was 3.63; P value was .156. Simulation training may boost residents’ comfort level, but not necessarily decrease patient discomfort during intra-articular knee injections.
Medical moulages of farm accidents
DeLoughery, Emma P. , Newman, James S.

Mayo Clinic

Internal Medicine Journal | July 9, 2018 | Volume: 48 | Issue: 7 | Pages: 882-884

10.1111/imj.13945 | PMID 29984509 Get It

AbstractAlthough popular for displaying dermatologic conditions before the advent of photography, the medical moulage has also illustrated injuries and accidents. Explored here are three farm accidents and the moulages based on them that occurred in rural Minnesota in the early 20th century. Besides being an object of historical interest, the medical moulage also provides a valuable learning and training opportunity, and can even be thought of as the predecessor of three dimensional printing.
Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?
Balko, Ryan , Hendrickson, Andrea Wahner, Grudem, Megan E. , Klampe, Carolyn M., Jatoi, Aminah , Balko, Ryan A

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | July 9, 2018 | Volume: 36 | Issue: 1 | Pages: 72-75

10.1177/1049909118786958 | PMID 29983087 Get It

Background: Paclitaxel-treated patients can suffer from years of peripheral neuropathy with pain, numbness, and tingling. Promising preclinical data with poly (ADP-ribose) polymerase (PARP) inhibitors led us to explore this class of agents to palliate this neuropathy. Methods: We relied on a completed trial that tested the antineoplastic effects of veliparib (NCT01012817). Data from patients who had been enrolled on NCT01012817, who previously received paclitaxel, and who had completed a validated pain assessment instrument were evaluated for improvement in their pain scores. Results: All 34 eligible patients were women, and all had a metastatic gynecological malignancy. On a 10-point scale (higher numbers indicative of worse pain), the average baseline score was 3.6 (range: 0-7). Seven patients (21%; 95% confidence interval: 9%-38%) manifested a drop in pain score (1 score lower than baseline followed by at least one consecutive value also below baseline). Of note, no patients initiated other therapy for neuropathy while on NCT01012817. Conclusion: The PARP inhibitors merit further study for chemotherapy-induced peripheral neuropathy. For patients suffering from peripheral neuropathy, these putative palliative effects might prompt earlier consideration of a PARP inhibitor as part of cancer treatment.
Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis
Mudireddy, Mythri , Gangat, Naseema , Finke, Christy M. , Hanson, Curtis A. , Ashrani, Aneel A. , Pardanani, Animesh , Nagorney, David M. , Tefferi, Ayalew , Lasho, Terra L. , Tefferi, Ayalew , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | July 7, 2018 | Volume: 93 | Issue: 9 | Pages: No page available

10.1002/ajh.25203 | PMID 29981287 Get It